{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T05:07:34Z","timestamp":1784092054584,"version":"3.55.0"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    This case report describes a 74-year-old female patient with lung adenocarcinoma harboring an\n                    <jats:italic>EGFR<\/jats:italic>\n                    exon 21 L858R variant and brain metastases. During sequential treatment with two third-generation epidermal growth factor receptor\u2013tyrosine kinase inhibitors (EGFR-TKIs), aumolertinib (formerly known as almonertinib) and furmonertinib, the patient developed severe exfoliative dermatitis (ED). Given the patient\u2019s poor performance status, chemotherapy was declined, and treatment was subsequently switched to the first-generation EGFR-TKI gefitinib. Gefitinib was well tolerated, and no recurrence of cutaneous reactions was observed. Follow-up chest computed tomography demonstrated stable disease, with disease control maintained for more than four months. This case highlights the importance of careful monitoring for severe and potentially life-threatening cutaneous adverse reactions, including ED, during treatment with third-generation EGFR-TKIs. The clinical course also suggests differences in cutaneous toxicity profiles among EGFR-TKIs of different generations. For patients who develop severe cutaneous toxicity with third-generation EGFR-TKIs, switching to a first-generation EGFR-TKI may represent a safe, feasible, and effective therapeutic alternative.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1843848","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:40:48Z","timestamp":1784090448000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Gefitinib treatment after exfoliative dermatitis induced by sequential aumolertinib and furmonertinib in lung adenocarcinoma: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Weifen","family":"Xiang","sequence":"first","affiliation":[{"name":"Department of Oncology, Dongyang People\u2019s Hospital Affiliated to Wenzhou Medical University","place":["Dongyang, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Dongyang People\u2019s Hospital Affiliated to Wenzhou Medical University","place":["Dongyang, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Oncology, Dongyang People\u2019s Hospital Affiliated to Wenzhou Medical University","place":["Dongyang, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Dongyang People\u2019s Hospital Affiliated to Wenzhou Medical University","place":["Dongyang, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Oncology, Dongyang People\u2019s Hospital Affiliated to Wenzhou Medical University","place":["Dongyang, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13987","article-title":"Malignancy-associated generalised exfoliative dermatitis: a retrospective study in a single-centre Asian cohort","volume":"64","author":"Long","year":"2023","journal-title":"Australas J Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.201027","article-title":"Hydroxychloroquine-induced erythroderma","volume":"49","author":"Pai","year":"2017","journal-title":"Indian J Pharmacol"},{"key":"B3","article-title":"Exfoliative dermatitis","volume-title":"Statpearls","author":"Austad","year":"2025"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-024-00886-9","article-title":"Deciphering the etiologies of adult erythroderma: an updated guide to presentations, diagnostic tools, pathophysiologies, and treatments","volume":"25","author":"Pang","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29570","article-title":"Nitrofurantoin-induced exfoliative dermatitis: a case report","volume":"14","author":"Morna","year":"2022","journal-title":"Cureus"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14625","article-title":"Erythroderma (exfoliative dermatitis). Part 1: underlying causes, clinical presentation and pathogenesis","volume":"46","author":"Tso","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45965","article-title":"Acute exfoliative dermatitis\/erythroderma secondary to gliclazide","volume":"15","author":"Al Badawi","year":"2023","journal-title":"Cureus"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.19381\/j.issn.1001-7585.2024.06.037","article-title":"A case of exfoliative dermatitis induced by amlodipine besylate tablets","volume":"37","author":"Liang","year":"2024","journal-title":"J Med Theory Pract"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02641","article-title":"AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations","volume":"40","author":"Lu","year":"2022","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1444707","article-title":"Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study","volume":"15","author":"Li","year":"2024","journal-title":"Front Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01695-2","article-title":"Aumolertinib: a review in non-small cell lung cancer","volume":"82","author":"Shirley","year":"2022","journal-title":"Drugs"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.13286\/j.1001-5213.2023.11.20","article-title":"A case of Stevens-Johnson syndrome caused by almonertinib","volume":"43","author":"Wang","year":"2023","journal-title":"Chin J Hosp Pharm"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.12144\/zgmfskin202402136","article-title":"A case of almonertinib induced bullotic toxic epidermal necrolysis","volume":"40","author":"Zhang","year":"2024","journal-title":"China J Lepr Skin Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/lctt.S385437","article-title":"Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, \"uncommon-G719X, S768I, L861Q\") among the third-generation EGFR TKIs","volume":"13","author":"Zhang","year":"2022","journal-title":"Lung Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12594","article-title":"Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS)","volume":"44","author":"Lu","year":"2024","journal-title":"Cancer Commun"},{"key":"B16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.clindermatol.2018.12.002","article-title":"The rash that becomes an erythroderma","volume":"37","author":"Inamadar","year":"2019","journal-title":"Clin Dermatol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1843848\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:41:00Z","timestamp":1784090460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1843848\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":16,"alternative-id":["10.3389\/fonc.2026.1843848"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1843848","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"1843848"}}